Cobimetinib

Brand names: Cotellic · Active ingredient: Cobimetinib Fumarate

In short: COTELLIC ® is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms.

Forms & strengthsTablets: 20 mg, white, round, film-coated, debossed on one side with "COB".
LabelGenentech, Inc.
Label updatedSep 02, 2026

What is Cobimetinib used for?

COTELLIC

®

is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.

COTELLIC®, as a single agent, is indicated for the treatment of adult patients with histiocytic neoplasms.

Cobimetinib dosage

Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with COTELLIC with vemurafenib. Information on FDA-approved tests for the detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.

The recommended dosage regimen of COTELLIC is 60 mg (three 20 mg tablets) orally taken once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity .

Take COTELLIC with or without food .

If a dose of COTELLIC is missed or if vomiting occurs when the dose is taken, resume dosing with the next scheduled dose.

Concurrent CYP3A Inhibitors

Do not take strong or moderate CYP3A inhibitors while taking COTELLIC.

If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking COTELLIC 60 mg, reduce COTELLIC dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume previous dose of COTELLIC 60 mg .

Use an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of COTELLIC (40 or 20 mg daily) .

Adverse Reactions

Review the Full Prescribing Information for vemurafenib for recommended dose modifications.

First Dose Reduction | 40 mg orally once daily

Second Dose Reduction | 20 mg orally once daily

Subsequent Modification | Permanently discontinue COTELLIC if unable to tolerate 20 mg orally once daily

Severity of Adverse ReactionNational Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0) | Dose Modification for COTELLIC

New Primary Malignancies (cutaneous and non-cutaneous) | No dose modification is required.

Hemorrhage

Grade 3 | Withhold COTELLIC for up to 4 weeks.

If improved to Grade 0 or 1, resume at the next lower dose level.

If not improved within 4 weeks, permanently discontinue.

Grade 4 | Permanently discontinue.

Cardiomyopathy

Asymptomatic, absolute decrease in LVEF from baseline of greater than 10% and less than institutional lower limit of normal (LLN) | Withhold COTELLIC for 2 weeks; repeat LVEF.

Resume at next lower dose if all of the following are present:

LVEF is at or above LLN and

Absolute decrease from baseline LVEF is 10% or less.

Permanently discontinue if any of the following are present:

LVEF is less than LLN or

Absolute decrease from baseline LVEF is more than 10%.

Symptomatic LVEF decrease from baseline | Withhold COTELLIC for up to 4 weeks, repeat LVEF.

Resume at next lower dose if all of the following are present:

Symptoms resolve and

LVEF is at or above LLN and

Absolute decrease from baseline LVEF is 10% or less. …

How to take Cobimetinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform patients of the following:

New primary cutaneous malignancies: Advise patients to contact their health care provider immediately for change in or development of new skin lesions .

Hemorrhage: Instruct patients to contact their healthcare provider to seek immediate medical attention for signs or symptoms of unusual severe bleeding or hemorrhage .

Cardiomyopathy: Advise patients to report any history of cardiac disease and of the requirement for cardiac monitoring prior to and during COTELLIC administration. Instruct patients to immediately report any signs or symptoms of left ventricular dysfunction to their healthcare provider .

Serious dermatologic reactions: Instruct patients to contact their healthcare provider to immediately report severe skin changes .

Serous retinopathy and retinal vein occlusion: Instruct patients to immediately contact their healthcare provider if they experience any changes in their vision .

Hepatotoxicity: Advise patients that treatment with COTELLIC requires monitoring of their liver function. …

Warnings & precautions

Do not take this medicine if: None.

Review the Full Prescribing Information for vemurafenib for information on the serious risks of vemurafenib.

New primary malignancies, cutaneous and non-cutaneous, can occur with COTELLIC.

Cutaneous Malignancies:

In Trial 1, the following cutaneous malignancies or premalignant conditions occurred in the COTELLIC with vemurafenib arm and the vemurafenib arm, respectively: cutaneous squamous cell carcinoma (cuSCC) or keratoacanthoma (KA) (6% and 20%), basal cell carcinoma (4.5% and 2.4%), and second primary melanoma (0.8% and 2.4%). Among patients receiving COTELLIC with vemurafenib, the median time to detection of first cuSCC/KA was 4 months (range: 2 to 11 months), and the median time to detection of basal cell carcinoma was 4 months (range: 27 days to 13 months). The time to onset in the two patients with second primary melanoma was 9 months and 12 months.

Perform dermatologic evaluations prior to initiation of therapy and every 2 months while on therapy. Manage suspicious skin lesions with excision and dermatopathologic evaluation. No dose modifications are recommended for COTELLIC . Conduct dermatologic monitoring for 6 months following discontinuation of COTELLIC when administered with vemurafenib.

Non-Cutaneous Malignancies:

Based on its mechanism of action, vemurafenib may promote growth and development of malignancies [refer to the Full Prescribing Information for vemurafenib]. In Trial 1, 0.8% of patients in the COTELLIC with vemurafenib arm and 1.2% of patients in the vemurafenib arm developed non-cutaneous malignancies.

Monitor patients receiving COTELLIC, when administered with vemurafenib, for signs or symptoms of non-cutaneous malignancies.

Hemorrhage, including major hemorrhages defined as symptomatic bleeding in a critical area or organ, can occur with COTELLIC. …

Cobimetinib side effects

The following adverse reactions are discussed in greater detail in other sections of the label:

New Primary Cutaneous Malignancies

Hemorrhage

Cardiomyopathy

Serious Dermatologic Reactions

Serous Retinopathy and Retinal Vein Occlusion

Hepatotoxicity

Rhabdomyolysis

Severe Photosensitivity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Unresectable or Metastatic Melanoma

The safety of COTELLIC was evaluated in Trial 1, a randomized (1:1), double-blind, active-controlled trial in previously untreated patients with BRAF V600 mutation-positive, unresectable or metastatic melanoma . All patients received vemurafenib 960 mg twice daily on Days 1–28 and received either COTELLIC 60 mg once daily (n=247) or placebo (n=246) on Days 1–21 of each 28-day treatment cycle until disease progression or unacceptable toxicity. In the COTELLIC plus vemurafenib arm, 66% percent of patients were exposed for greater than 6 months and 24% of patients were exposed for greater than 1 year. Patients with abnormal liver function tests, history of acute coronary syndrome within 6 months, evidence of Class II or greater congestive heart failure (New York Heart Association), active central nervous system lesions, or evidence of retinal pathology were excluded from Trial 1. …

Drug interactions

Coadministration of COTELLIC with itraconazole (a strong CYP3A4 inhibitor) increased cobimetinib systemic exposure by 6.7-fold. Avoid concurrent use of COTELLIC and strong or moderate CYP3A inhibitors. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors including certain antibiotics (e.g., erythromycin, ciprofloxacin) is unavoidable for patients who are taking COTELLIC 60 mg, reduce COTELLIC dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume COTELLIC at the previous dose . Use an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of COTELLIC (40 or 20 mg daily) .

Coadministration of COTELLIC with a strong CYP3A inducer may decrease cobimetinib systemic exposure by more than 80% and reduce its efficacy. Avoid concurrent use of COTELLIC and strong or moderate CYP3A inducers including but not limited to carbamazepine, efavirenz, phenytoin, rifampin, and St. John's Wort .

About this medicine

Cobimetinib fumarate is a kinase inhibitor. The chemical name is (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemifumarate. It has a molecular formula C46H46F6I2N6O8 (2 C21H21F3IN3O2 ∙ C4H4O4) with a molecular mass of 1178.71 as a fumarate salt. Cobimetinib fumarate has the following chemical structure:

Cobimetinib is a fumarate salt appearing as white to off-white solid and exhibits a pH dependent solubility.

COTELLIC (cobimetinib) tablets are supplied as white, round, film-coated 20 mg tablets for oral administration, debossed on one side with "COB". Each 20 mg tablet contains 22 mg of cobimetinib fumarate, which corresponds to 20 mg of the cobimetinib free base.

The inactive ingredients of COTELLIC are: Tablet Core: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate. Coating: polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c387579e-cee0-4334-bd1e-73f93ac1bde6. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate